Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer

Although nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is approved to be given every 3 weeks, weekly use of this drug is becoming a new standard of care in patients with metastatic breast cancer (MBC). This prospective Phase II study was conducted to improve the efficacy of weekly nab-pacli...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Sun, Si, Tang, Lichen, Zhang, Jian, Lv, Fangfang, Wang, Zhonghua, Wang, Leiping, Zhang, Qunling, Zheng, Chunlei, Qiu, Lixin, Jia, Zhen, Lu, Yunhua, Liu, Guangyu, Shao, Zhimin, Wang, Biyun, Hu, Xichun
Формат: Artigo
Язык:Inglês
Опубликовано: Dove Medical Press 2014
Предметы:
Original Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3964033/
https://ncbi.nlm.nih.gov/pubmed/24672237
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJN.S58275
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы